Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
4.1
3.0
Journals
JPM
Special Issues
Novel Challenges and Advances in Pediatric Hematology and Hematologic Malignancies
share announcement

Novel Challenges and Advances in Pediatric Hematology and Hematologic Malignancies

A special issue of Journal of Personalized Medicine (ISSN 2075-4426). This special issue belongs to the section "Mechanisms of Diseases".

Deadline for manuscript submissions: 25 April 2025 | Viewed by 692

Special Issue Editor

Dr. Katarzyna Pawińska-Wa̧sikowska

E-Mail Website
Guest Editor
Department of Pediatric Oncology and Hematology, University Children’s Hospital, Jagiellonian University Medical College, 31-008 Krakow, Poland
Interests: leukemia; lymphoma; neuroblastoma; hepatoblastoma; nephroblastoma; pediatric hematology; immunotherapyerapy

Special Issue Information

Dear Colleagues,

Recent advancements have significantly improved diagnostics and therapies in pediatric hematology and hematologic malignancies. Immunotherapies, hematopoietic stem cell transplantation in nonmalignant and malignant hematological disorders, the introduction of long half-life coagulation products for patients with hemophilia, and many others have significantly changed the picture of pediatric hematology. However, there is a continuous need for further development in many fields of patient care to improve the prognosis and quality of life for children with hematologic disorders and malignancies.

The Special Issue aims to highlight the latest advances in the clinical, genetic, and therapeutic aspects of children with hematologic disorders or malignancies to provide better information to further improve diagnosis and treatment.

We cordially welcome original research and review submissions covering, but not limited to, the following topics:

  • Advances in the diagnosis and therapies of red blood disorders;
  • Modern therapies in hemophilia;
  • New insights into the diagnosis, prognosis, and therapies of children with thrombocytopenia;
  • Recent advances in therapeutic approaches to lymphoid and myeloid neoplasms, including immunotherapies;
  • Advances in supportive care measure developments for hematologic patients.

Dr. Katarzyna Pawińska-Wa̧sikowska
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Personalized Medicine is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • pediatric hematology
  • hematology malignancies
  • therapies
  • diagnosis
  • immunotherapies
  • supportive care

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

12 pages, 1417 KiB  
Article
Use of Granulocyte Transfusions in the Management of Severe Infections Among Children with Neutropenia
by Gabriela Mielecka-Jarmocik, Katarzyna Szymbor, Walentyna Balwierz, Szymon Skoczeń, Marta Leń, Kinga Kania and Katarzyna Pawińska-Wąsikowska
J. Pers. Med. 2024, 14(11), 1107; https://doi.org/10.3390/jpm14111107 - 15 Nov 2024
Viewed by 432
Abstract
Background/Objectives: Infections remain the leading cause of mortality among neutropenic patients with haematologic malignancies, making effective infection management crucial. Achieving a sufficient neutrophil count is essential for the elimination of pathogens. Granulocyte concentrate (GC) can be a treatment option for neutropenic patients with [...] Read more.
Background/Objectives: Infections remain the leading cause of mortality among neutropenic patients with haematologic malignancies, making effective infection management crucial. Achieving a sufficient neutrophil count is essential for the elimination of pathogens. Granulocyte concentrate (GC) can be a treatment option for neutropenic patients with severe infections. This study aimed to evaluate the efficacy, safety, and impact on survival of GC transfusions in neutropenic children with severe infections treated over the past 13 years in a single centre. Methods: The retrospective study analysed clinical data from 60 children (median age 9.5 years) who received GC transfusions at our centre. Granulocytes were collected by apheresis from donors stimulated with granulocyte colony-stimulating factor. The majority of the patients (70%) were diagnosed with acute leukaemia. The main indications for GC were severe pneumonia (45%) and bacterial sepsis (38.33%). Results: The patients received 1 to 29 GC transfusions for 1 to 70 days, with a median time of administration of 3 days. Neutrophil counts increased to >1000/µL within a median of 5 days. GCs were well tolerated by most patients. One patient presented symptoms of anaphylaxis, the other acute lung injury related to transfusions, and alloimmunisation was reported in one patient. Of the patients analysed, 78.33% survived the infection that justified GC administration. We did not observe significant differences in survival depending on the aetiology of the infection. Conclusions: Based on our research, GC appears to be a beneficiary for neutropenic children with severe infections and reduces infection mortality rates. However, further well-designed randomised trials are needed to define its role in this setting. Full article
(This article belongs to the Special Issue Novel Challenges and Advances in Pediatric Hematology and Hematologic Malignancies)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop